



# The First Impact Factor for *Translational Lung Cancer Research*: 4.806

## Editorial Office

Editorial Office of Translational Lung Cancer Research, AME Publishing Company, Hong Kong, China

Correspondence to: Editorial Office. Translational Lung Cancer Research, AME Publishing Company, Hong Kong, China. Email: editor@tlcr.org.

Submitted Jun 20, 2019. Accepted for publication Jun 21, 2018.

doi: 10.21037/tlcr.2019.06.13

View this article at: <http://dx.doi.org/10.21037/tlcr.2019.06.13>

We are pleased to announce to our readers that *Translational Lung Cancer Research (TLCR)* has attained its first impact factor for the 2018 citation year: 4.806 (Figure 1).

The impact factor, as published in the annual Journal Citation Reports (JCR), is a calculation determined based on the number of citations accumulated in 2018 for manuscripts published in 2016 and 2017.

*Translational Lung Cancer Research* is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.

The release of the journal's first impact factor is not only a significant achievement for the journal, but it is also the beginning of developing a more significant scientific reach. Here, we would like to extend our heartfelt gratitude to all our Editorial Team Members, Guest Editors, authors, and reviewers for their significant contributions. We look forward to the continuous cooperation with all the above mentioned and those who are interested in translational lung cancer research to bring more exciting content to



Figure 1 *Translational Lung Cancer Research (TLCR)* has attained its first impact factor for the 2018 citation year: 4.806.

readers in the coming future.

## Acknowledgments

None.

## Footnote

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Cite this article as:** Editorial Office. The First Impact Factor for *Translational Lung Cancer Research*: 4.806. *Transl Lung Cancer Res* 2019;8(3):E1. doi: 10.21037/tlcr.2019.06.13